Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q5EBL4
UPID:
RIPL1_HUMAN
Alternative names:
Rab-interacting lysosomal-like protein 1
Alternative UPACC:
Q5EBL4; Q66K36; Q8N1M0
Background:
RILP-like protein 1, alternatively known as Rab-interacting lysosomal-like protein 1, is pivotal in cell shape regulation and polarity. It plays a crucial role in cellular protein transport, including away from primary cilia, and acts as a neuroprotective agent by sequestering GAPDH in the cytosol. This protein is also involved in the inhibition of ciliogenesis through its interaction with RAB10 following LRRK2-mediated phosphorylation.
Therapeutic significance:
RILP-like protein 1's association with Oculopharyngodistal myopathy 4, a muscle disorder characterized by progressive muscle weakness, highlights its therapeutic potential. Understanding the role of RILP-like protein 1 could open doors to potential therapeutic strategies for treating this debilitating condition.